Vanda Pharmaceuticals Inc.

VNDA Healthcare Biotechnology

Vanda Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $216.1 million, up 8.72% from fiscal 2024. In the quarter to June 2026, revenue fell 3.92%, EPS fell 126.1%, free cash flow fell 101.0% and total debt rose 2.98%, each against the same quarter a year earlier.

4.03 0.21 −4.95%
Market cap
$256.4M
P/E
0.0×
Fwd P/E
−2.6×
Dividend yield
—
F-score
2/9
Altman Z
0.72
Beneish M
−3.88
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
1.39 2.41 1.89 1.71
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(9.32) (17.67) (8.18) (11.86)
P/B ratio
0.63 1.59 1.46 1.67
Price to Tangible BV
0.83 2.47 2.48 3.44
EV/Sales
0.02 1.20 0.98 0.94
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
(0.05) (2.38) (1.68) (1.42)
EV/FCF
(0.05) (2.35) (1.55) (1.32)
Quick Ratio
2.92 2.19 1.91 1.40
Current Ratio
3.12 2.39 2.16 1.61
Net Debt/EBITDA
9.25 7.48 4.24 2.77
Debt/Assets
0.47% 0.83% 0.87% 0.77%
Debt/Equity
0.01 0.01 0.01 0.01
Asset Turnover
0.34 0.38 0.41 0.42
Operating CF/Net income
1.40 0.21 1.03 0.50
Capex/Depreciation
1.02 (0.02) (3.01) (0.05)
Research and Development Expense of Revenue
40.11% 50.70% 54.98% 73.13%
Selling, General and Administrative Expense of Revenue
107.14% 110.07% 132.18% 142.17%
Intangible Assets out of Total Assets
0.18 0.24 0.27 0.27
Share Based Compensation of Revenue
3.75% 3.99% 4.96% 4.17%
Graham Net Nets
0.79 0.36 0.34 0.20
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(28.46%) (42.29%) (58.61%) (75.65%)
Free Cash Flow Yield
(28.13%) (21.25%) (33.42%) (41.51%)
Revenue per Share
0.95 0.97 0.87 0.84
Operating CF per Share
(0.54) (0.50) (0.84) (0.52)
Capex per Share
0.00 0.00 (0.17) 0.00
Free Cash Flow per Share
(0.54) (0.50) (1.02) (0.52)
Cash per Share
4.97 4.48 3.40 2.82
Shareholders Equity per Share
7.89 5.55 4.72 3.66
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
7.89 5.55 4.72 3.66
Free Cash Flow
(31.79) (29.52) (60.44) (31.26)
Working Capital
249.63 202.10 157.59 100.46
Capital Expenditures
(0.16) (0.10) (10.22) (0.19)
Net Current Asset Value
232.36 185.50 140.41 72.20
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.00 0.00 0.20 0.00
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
46.65 50.84 50.74 52.34
Average Payables
43.46 53.69 52.95 63.56
Average Inventory
1.83 1.79 1.81 1.92
Average Assets
623.13 572.58 532.73 518.61
Average Common Equity
503.61 432.87 396.09 353.26

Fold the line items

Columns are period end dates